Vita Coco (COCO) Q2 2026 earnings review
Massive Margin Spike and Private Label Rebound Drive a Guidance Raise
Vita Coco delivered a phenomenal second quarter, blowing past last year's figures across the board. Net sales accelerated 28% year-over-year to $216 million, largely driven by an explosive 78% volume recovery in the Private Label business and continued strength in core branded coconut water (+21%). The bottom line stole the show: Net Income more than doubled to $49 million, fueled by a 700 basis point margin benefit from recognized tariff refunds. Armed with strong momentum and $279 million in cash, management significantly raised FY26 guidance and announced the acquisition of Copra to enter the super-premium segment.
🐂 Bull Case
After struggling with lost contracts and severe volume declines in 2025, Private Label has completely reversed course. Q2 case equivalent (CE) volume skyrocketed 78%, vindicating management's strategy to regain distribution and add new major retail partners.
The highly uncertain IEEPA tariff situation from early 2026 has resolved favorably. The company successfully realized refunds, structurally boosting Q2 gross margin to 49% (from 36% last year) and elevating the baseline profitability profile.
🐻 Bear Case
While Q2 margins hit 49% and YTD margins sit at 45%, full-year guidance was set to '~40%'. This implies second-half gross margins will decelerate significantly down to the mid-30s due to fading refund benefits, higher input costs, and shifting mix.
The 'Other' product category (which houses recent innovations like Vita Coco Treats) saw volume growth grind to a near halt at +1.9% in Q2, down drastically from +202% a year ago. The market may question the long-term viability of these brand extensions.
⚖️ Verdict: 🟢🟢
Highly Bullish. The company resolved its two biggest overhangs from 2025—Private Label losses and tariff risks—while maintaining over 20% growth in its core, high-margin branded business. The resulting cash generation allows for accretive M&A and increased stock buybacks.
Key Themes
Private Label Business Reversing from Drag to Growth Engine
Vita Coco's Private Label segment achieved a spectacular turnaround. In 25Q2, the segment was a massive headwind with volume down 22% overall and 34% in the Americas. This quarter, Private Label volumes surged 78% globally (81.7% in the Americas), translating to a near-doubling of revenue to $38.2 million. This rapid onboarding of new and regained business proves the stickiness and necessity of Vita Coco's global supply chain to major retailers.
Margin Expansion Led by Tariff Refunds and Pricing
Gross margin exploded to 48.7%, up 1,240 basis points from 36.3% a year ago. While 700 bps of this was a direct injection from tariff refunds, the underlying core gross margin still expanded robustly to roughly 41.7%. Lower ocean freight, lower finished goods costs, and the residual impact of 2025 price increases are generating tremendous operating leverage.
International Mainstreaming
The international segment continues to validate management's thesis that coconut water is mainstreaming globally. International net sales grew 63% to $43.7 million. Crucially, International Vita Coco Coconut Water case volumes jumped 60.3%, accelerating from 45% growth in Q1. The runway in Europe remains extensive as penetration catches up to US levels.
Sudden Deceleration in 'Other' Innovation Products
The 'Other' product segment, heavily reliant on the Vita Coco Treats milk-beverage innovation launched in 2025, hit a brick wall. Total volume growth for 'Other' fell to just +1.9% in Q2, compared to +15.6% in Q1 and over +200% a year ago. International 'Other' volumes outright collapsed (-78.5%). This strongly suggests repeat purchase rates for Treats may be failing to materialize, confining growth strictly to the core coconut water.
M&A Strategy Activated: Copra Acquisition
With the balance sheet pristine ($279M cash, zero debt), Vita Coco executed its first meaningful M&A transaction by acquiring Copra, Inc. This instantly gives Vita Coco a credible foothold in the super-premium, perishable 'Thai Nam Hom' segment of the category, which commands significantly higher retail price points and appeals to an even more health-conscious demographic.
Other KPIs
Accelerating. Up 130% from $29.2 million in the prior year period. The flow-through from the 28% top-line increase and the 700 bps tariff refund benefit heavily outweighed the $6 million increase in SG&A expenses. YTD Adjusted EBITDA sits at $105.9M, representing 66% of the new full-year guidance midpoint.
Up sharply from $196.9 million at year-end 2025. The company’s cash generation machine is running perfectly, converting strong net income directly to cash while actively drawing down inventory (which fell from $111.5M at year-end to $82.9M). This massive liquidity pile easily funded the expanded $105M share repurchase authorization.
Guidance
Accelerating. Raised significantly from the prior $720-$735 million range. The midpoint of $797.5M implies ~31% full-year growth compared to FY25's $610M. This implies second-half sales of roughly $401 million, sustaining a healthy ~22% implied YoY growth rate for H2.
Accelerating. Raised from $132-$138 million. The new midpoint ($157.5M) implies massive 60% YoY growth over FY25's $98M. However, with $106M generated in H1, the implied H2 Adjusted EBITDA is roughly $51.5M—a material sequential deceleration reflecting the lack of tariff refunds in the back half and increased marketing investments.
Decelerating implicitly for H2. Raised from the prior guide of 38%. With H1 delivering a 44.7% gross margin, maintaining a 40% average for the full year mathmatically requires second-half margins to compress down to approximately 35-36%. Management flagged current cost pressures and adverse product mix as the culprits for the balance of the year.
Key Questions
Super-Premium Strategy with Copra
How will Copra be integrated into the existing supply chain and distribution network? Does this acquisition signal a shift toward refrigerated/perishable distribution capabilities?
H2 Margin Compression Drivers
The implied second-half gross margin drops to the mid-30s. How much of this compression is purely the absence of Q2's one-time tariff refund versus actual worsening of input costs like ocean freight and fuel surcharges?
Vita Coco Treats Traction
Volume growth in the 'Other' category decelerated to under 2% this quarter. Are we seeing a plateau in consumer interest for Treats, and how does this alter the innovation pipeline strategy for 2027?
Capital Allocation Hierarchy
With the Copra acquisition announced and $279M in cash still on the balance sheet, should investors expect an acceleration in share repurchases under the expanded $105M authorization, or are more M&A targets currently being evaluated?